TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media

Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Research Report 2023

Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Research Report 2023

  • Category:Life Sciences
  • Published on : 12 May 2023
  • Pages :101
  • Formats:
  • Report Code:SMR-7684236
OfferClick for best price

Best Price: $2320

Cancer Monoclonal Antibody Partnering Terms Agreements Market Size, Share 2023


Market Analysis and Insights: Global Cancer Monoclonal Antibody Partnering Terms Agreements Market

The global Cancer Monoclonal Antibody Partnering Terms Agreements market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Cancer Monoclonal Antibody Partnering Terms Agreements market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Cancer Monoclonal Antibody Partnering Terms Agreements market in terms of revenue.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Cancer Monoclonal Antibody Partnering Terms Agreements market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Cancer Monoclonal Antibody Partnering Terms Agreements market.

Global Cancer Monoclonal Antibody Partnering Terms Agreements Scope and Market Size

Cancer Monoclonal Antibody Partnering Terms and Agreements market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Cancer Monoclonal Antibody Partnering Terms and Agreements market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2018-2029.

Segment by Type

Segment by Application

  • Pharmaceutical Industry
  • Biotechnology
  • Medical Care
  • Education and Research
  • Other

By Region

  • North America
  • United States
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Russia
  • Nordic Countries
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia
  • Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
  • Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

By Company

  • 3SBio
  • 4D Pharma
  • Abbvie
  • Abzena
  • Adaptive Biotechnologies
  • Aeglea BioTherapeutics
  • Agenus Bio
  • Ascension
  • Ascentage Pharma
  • Aslan Pharma
  • Telix Pharmaceuticals
  • Basilea Pharmaceutica
  • Bavarian Nordic
  • Baxalta
  • Bayer
  • Cantargia
  • Apollomics
  • Chiome Bioscience
  • Clovis Oncology

The information for each competitor/Company Profile includes:

  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis 

The content of the study subjects includes a total of 15 chapters:

Chapter 1, describes Cancer Monoclonal Antibody Partnering Terms Agreements product scope, market overview, market opportunities, market driving force, and market risks.

Chapter 2, profiles the top manufacturers of Cancer Monoclonal Antibody Partnering Terms Agreements, with price, sales, revenue, and global market share of Cancer Monoclonal Antibody Partnering Terms Agreements from 2019 to 2022.

Chapter 3, the Cancer Monoclonal Antibody Partnering Terms Agreements competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Cancer Monoclonal Antibody Partnering Terms Agreements breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.

Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.

Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the Cancer Monoclonal Antibody Partnering Terms Agreements market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.

Chapter 12, the key raw materials and key suppliers, and industry chain of Cancer Monoclonal Antibody Partnering Terms Agreements.

Chapter 13, 14, and 15, to describe Cancer Monoclonal Antibody Partnering Terms Agreements sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Key Indicators Analysed:

  • Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
  • Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
  • Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
  • Opportunities and Drivers: Identifying the Growing Demands and New Technology
  • Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

Reasons to Purchase this Report:

  • Estimates 2022-2027 2021-2025 Cancer Monoclonal Antibody Partnering Terms Agreements Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
  • Market dynamics scenario, along with growth opportunities of the market in the years to come
  • Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
  • Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
  • Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
  • Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
  • Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
  • 1-year analyst support, along with the data support in excel format.

Research Methodology:

The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Report Attributes Report Details
Report Title Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Research Report 2023
Historical Year 2018 to 2022 (Data from 2010 can be provided as per availability)
Base Year 2022
Forecast Year 2030
Number of Pages 101 Pages
Customization Available Yes, the report can be customized as per your need.

TABLE OF CONTENTS

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Asset Purchase
1.2.3 Collaborative R&D
1.2.4 Joint Venture
1.2.5 Licensing
1.2.6 Other
1.3 Market by Application
1.3.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Application: 2018 VS 2022 VS 2029
1.3.2 Pharmaceutical Industry
1.3.3 Biotechnology
1.3.4 Medical Care
1.3.5 Education and Research
1.3.6 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Perspective (2018-2029)
2.2 Cancer Monoclonal Antibody Partnering Terms and Agreements Growth Trends by Region
2.2.1 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Cancer Monoclonal Antibody Partnering Terms and Agreements Historic Market Size by Region (2018-2023)
2.2.3 Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Region (2024-2029)
2.3 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Dynamics
2.3.1 Cancer Monoclonal Antibody Partnering Terms and Agreements Industry Trends
2.3.2 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Drivers
2.3.3 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Challenges
2.3.4 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cancer Monoclonal Antibody Partnering Terms and Agreements Players by Revenue
3.1.1 Global Top Cancer Monoclonal Antibody Partnering Terms and Agreements Players by Revenue (2018-2023)
3.1.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Players (2018-2023)
3.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue
3.4 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Concentration Ratio
3.4.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in 2022
3.5 Cancer Monoclonal Antibody Partnering Terms and Agreements Key Players Head office and Area Served
3.6 Key Players Cancer Monoclonal Antibody Partnering Terms and Agreements Product Solution and Service
3.7 Date of Enter into Cancer Monoclonal Antibody Partnering Terms and Agreements Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Cancer Monoclonal Antibody Partnering Terms and Agreements Breakdown Data by Type
4.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Historic Market Size by Type (2018-2023)
4.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Type (2024-2029)
5 Cancer Monoclonal Antibody Partnering Terms and Agreements Breakdown Data by Application
5.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Historic Market Size by Application (2018-2023)
5.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2018-2029)
6.2 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2018-2023)
6.3 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2024-2029)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2018-2029)
7.2 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2018-2023)
7.3 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2024-2029)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2018-2029)
8.2 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2018-2023)
8.3 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2024-2029)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2018-2029)
9.2 Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2018-2023)
9.3 Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2024-2029)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2018-2029)
10.2 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2018-2023)
10.3 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2024-2029)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 3SBio
11.1.1 3SBio Company Detail
11.1.2 3SBio Business Overview
11.1.3 3SBio Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.1.4 3SBio Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.1.5 3SBio Recent Development
11.2 4D Pharma
11.2.1 4D Pharma Company Detail
11.2.2 4D Pharma Business Overview
11.2.3 4D Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.2.4 4D Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.2.5 4D Pharma Recent Development
11.3 Abbvie
11.3.1 Abbvie Company Detail
11.3.2 Abbvie Business Overview
11.3.3 Abbvie Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.3.4 Abbvie Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.3.5 Abbvie Recent Development
11.4 Abzena
11.4.1 Abzena Company Detail
11.4.2 Abzena Business Overview
11.4.3 Abzena Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.4.4 Abzena Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.4.5 Abzena Recent Development
11.5 Adaptive Biotechnologies
11.5.1 Adaptive Biotechnologies Company Detail
11.5.2 Adaptive Biotechnologies Business Overview
11.5.3 Adaptive Biotechnologies Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.5.4 Adaptive Biotechnologies Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.5.5 Adaptive Biotechnologies Recent Development
11.6 Aeglea BioTherapeutics
11.6.1 Aeglea BioTherapeutics Company Detail
11.6.2 Aeglea BioTherapeutics Business Overview
11.6.3 Aeglea BioTherapeutics Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.6.4 Aeglea BioTherapeutics Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.6.5 Aeglea BioTherapeutics Recent Development
11.7 Agenus Bio
11.7.1 Agenus Bio Company Detail
11.7.2 Agenus Bio Business Overview
11.7.3 Agenus Bio Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.7.4 Agenus Bio Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.7.5 Agenus Bio Recent Development
11.8 Ascension
11.8.1 Ascension Company Detail
11.8.2 Ascension Business Overview
11.8.3 Ascension Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.8.4 Ascension Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.8.5 Ascension Recent Development
11.9 Ascentage Pharma
11.9.1 Ascentage Pharma Company Detail
11.9.2 Ascentage Pharma Business Overview
11.9.3 Ascentage Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.9.4 Ascentage Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.9.5 Ascentage Pharma Recent Development
11.10 Aslan Pharma
11.10.1 Aslan Pharma Company Detail
11.10.2 Aslan Pharma Business Overview
11.10.3 Aslan Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.10.4 Aslan Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.10.5 Aslan Pharma Recent Development
11.11 Telix Pharmaceuticals
11.11.1 Telix Pharmaceuticals Company Detail
11.11.2 Telix Pharmaceuticals Business Overview
11.11.3 Telix Pharmaceuticals Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.11.4 Telix Pharmaceuticals Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.11.5 Telix Pharmaceuticals Recent Development
11.12 Basilea Pharmaceutica
11.12.1 Basilea Pharmaceutica Company Detail
11.12.2 Basilea Pharmaceutica Business Overview
11.12.3 Basilea Pharmaceutica Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.12.4 Basilea Pharmaceutica Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.12.5 Basilea Pharmaceutica Recent Development
11.13 Bavarian Nordic
11.13.1 Bavarian Nordic Company Detail
11.13.2 Bavarian Nordic Business Overview
11.13.3 Bavarian Nordic Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.13.4 Bavarian Nordic Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.13.5 Bavarian Nordic Recent Development
11.14 Baxalta
11.14.1 Baxalta Company Detail
11.14.2 Baxalta Business Overview
11.14.3 Baxalta Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.14.4 Baxalta Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.14.5 Baxalta Recent Development
11.15 Bayer
11.15.1 Bayer Company Detail
11.15.2 Bayer Business Overview
11.15.3 Bayer Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.15.4 Bayer Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.15.5 Bayer Recent Development
11.16 Cantargia
11.16.1 Cantargia Company Detail
11.16.2 Cantargia Business Overview
11.16.3 Cantargia Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.16.4 Cantargia Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.16.5 Cantargia Recent Development
11.17 Apollomics
11.17.1 Apollomics Company Detail
11.17.2 Apollomics Business Overview
11.17.3 Apollomics Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.17.4 Apollomics Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.17.5 Apollomics Recent Development
11.18 Chiome Bioscience
11.18.1 Chiome Bioscience Company Detail
11.18.2 Chiome Bioscience Business Overview
11.18.3 Chiome Bioscience Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.18.4 Chiome Bioscience Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.18.5 Chiome Bioscience Recent Development
11.19 Clovis Oncology
11.19.1 Clovis Oncology Company Detail
11.19.2 Clovis Oncology Business Overview
11.19.3 Clovis Oncology Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
11.19.4 Clovis Oncology Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
11.19.5 Clovis Oncology Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

LIST OF TABLES & FIGURES

List of Tables
Table 1. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Asset Purchase
Table 3. Key Players of Collaborative R&D
Table 4. Key Players of Joint Venture
Table 5. Key Players of Licensing
Table 6. Key Players of Other
Table 7. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 9. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region (2018-2023) & (US$ Million)
Table 10. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Region (2018-2023)
Table 11. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 12. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Region (2024-2029)
Table 13. Cancer Monoclonal Antibody Partnering Terms and Agreements Market Trends
Table 14. Cancer Monoclonal Antibody Partnering Terms and Agreements Market Drivers
Table 15. Cancer Monoclonal Antibody Partnering Terms and Agreements Market Challenges
Table 16. Cancer Monoclonal Antibody Partnering Terms and Agreements Market Restraints
Table 17. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue by Players (2018-2023) & (US$ Million)
Table 18. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Players (2018-2023)
Table 19. Global Top Cancer Monoclonal Antibody Partnering Terms and Agreements Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements as of 2022)
Table 20. Ranking of Global Top Cancer Monoclonal Antibody Partnering Terms and Agreements Companies by Revenue (US$ Million) in 2022
Table 21. Global 5 Largest Players Market Share by Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (CR5 and HHI) & (2018-2023)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Cancer Monoclonal Antibody Partnering Terms and Agreements Product Solution and Service
Table 24. Date of Enter into Cancer Monoclonal Antibody Partnering Terms and Agreements Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2018-2023) & (US$ Million)
Table 27. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Type (2018-2023)
Table 28. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 29. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Type (2024-2029)
Table 30. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2018-2023) & (US$ Million)
Table 31. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Application (2018-2023)
Table 32. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 33. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Application (2024-2029)
Table 34. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2018-2023) & (US$ Million)
Table 35. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2024-2029) & (US$ Million)
Table 36. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2018-2023) & (US$ Million)
Table 37. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2024-2029) & (US$ Million)
Table 38. Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region (2018-2023) & (US$ Million)
Table 39. Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region (2024-2029) & (US$ Million)
Table 40. Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2018-2023) & (US$ Million)
Table 41. Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2024-2029) & (US$ Million)
Table 42. Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2018-2023) & (US$ Million)
Table 43. Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2024-2029) & (US$ Million)
Table 44. 3SBio Company Detail
Table 45. 3SBio Business Overview
Table 46. 3SBio Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 47. 3SBio Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023) & (US$ Million)
Table 48. 3SBio Recent Development
Table 49. 4D Pharma Company Detail
Table 50. 4D Pharma Business Overview
Table 51. 4D Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 52. 4D Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023) & (US$ Million)
Table 53. 4D Pharma Recent Development
Table 54. Abbvie Company Detail
Table 55. Abbvie Business Overview
Table 56. Abbvie Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 57. Abbvie Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023) & (US$ Million)
Table 58. Abbvie Recent Development
Table 59. Abzena Company Detail
Table 60. Abzena Business Overview
Table 61. Abzena Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 62. Abzena Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023) & (US$ Million)
Table 63. Abzena Recent Development
Table 64. Adaptive Biotechnologies Company Detail
Table 65. Adaptive Biotechnologies Business Overview
Table 66. Adaptive Biotechnologies Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 67. Adaptive Biotechnologies Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023) & (US$ Million)
Table 68. Adaptive Biotechnologies Recent Development
Table 69. Aeglea BioTherapeutics Company Detail
Table 70. Aeglea BioTherapeutics Business Overview
Table 71. Aeglea BioTherapeutics Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 72. Aeglea BioTherapeutics Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023) & (US$ Million)
Table 73. Aeglea BioTherapeutics Recent Development
Table 74. Agenus Bio Company Detail
Table 75. Agenus Bio Business Overview
Table 76. Agenus Bio Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 77. Agenus Bio Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023) & (US$ Million)
Table 78. Agenus Bio Recent Development
Table 79. Ascension Company Detail
Table 80. Ascension Business Overview
Table 81. Ascension Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 82. Ascension Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023) & (US$ Million)
Table 83. Ascension Recent Development
Table 84. Ascentage Pharma Company Detail
Table 85. Ascentage Pharma Business Overview
Table 86. Ascentage Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 87. Ascentage Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023) & (US$ Million)
Table 88. Ascentage Pharma Recent Development
Table 89. Aslan Pharma Company Detail
Table 90. Aslan Pharma Business Overview
Table 91. Aslan Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Product
Table 92. Aslan Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023) & (US$ Million)
Table 93. Aslan Pharma Recent Development
Table 94. Telix Pharmaceuticals Company Detail
Table 95. Telix Pharmaceuticals Business Overview
Table 96. Telix Pharmaceuticals Cancer Monoclonal Antibody Partnering Terms and AgreementsProduct
Table 97. Telix Pharmaceuticals Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023) & (US$ Million)
Table 98. Telix Pharmaceuticals Recent Development
Table 99. Basilea Pharmaceutica Company Detail
Table 100. Basilea Pharmaceutica Business Overview
Table 101. Basilea Pharmaceutica Cancer Monoclonal Antibody Partnering Terms and AgreementsProduct
Table 102. Basilea Pharmaceutica Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023) & (US$ Million)
Table 103. Basilea Pharmaceutica Recent Development
Table 104. Bavarian Nordic Company Detail
Table 105. Bavarian Nordic Business Overview
Table 106. Bavarian Nordic Cancer Monoclonal Antibody Partnering Terms and AgreementsProduct
Table 107. Bavarian Nordic Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023) & (US$ Million)
Table 108. Bavarian Nordic Recent Development
Table 109. Baxalta Company Detail
Table 110. Baxalta Business Overview
Table 111. Baxalta Cancer Monoclonal Antibody Partnering Terms and AgreementsProduct
Table 112. Baxalta Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023) & (US$ Million)
Table 113. Baxalta Recent Development
Table 114. Bayer Company Detail
Table 115. Bayer Business Overview
Table 116. Bayer Cancer Monoclonal Antibody Partnering Terms and AgreementsProduct
Table 117. Bayer Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023) & (US$ Million)
Table 118. Bayer Recent Development
Table 119. Cantargia Company Detail
Table 120. Cantargia Business Overview
Table 121. Cantargia Cancer Monoclonal Antibody Partnering Terms and AgreementsProduct
Table 122. Cantargia Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023) & (US$ Million)
Table 123. Cantargia Recent Development
Table 124. Apollomics Company Detail
Table 125. Apollomics Business Overview
Table 126. Apollomics Cancer Monoclonal Antibody Partnering Terms and AgreementsProduct
Table 127. Apollomics Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023) & (US$ Million)
Table 128. Apollomics Recent Development
Table 129. Chiome Bioscience Company Detail
Table 130. Chiome Bioscience Business Overview
Table 131. Chiome Bioscience Cancer Monoclonal Antibody Partnering Terms and AgreementsProduct
Table 132. Chiome Bioscience Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023) & (US$ Million)
Table 133. Chiome Bioscience Recent Development
Table 134. Clovis Oncology Company Detail
Table 135. Clovis Oncology Business Overview
Table 136. Clovis Oncology Cancer Monoclonal Antibody Partnering Terms and AgreementsProduct
Table 137. Clovis Oncology Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023) & (US$ Million)
Table 138. Clovis Oncology Recent Development
Table 139. Research Programs/Design for This Report
Table 140. Key Data Information from Secondary Sources
Table 141. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Type: 2022 VS 2029
Figure 2. Asset Purchase Features
Figure 3. Collaborative R&D Features
Figure 4. Joint Venture Features
Figure 5. Licensing Features
Figure 6. Other Features
Figure 7. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Application in 2022 & 2029
Figure 8. Pharmaceutical Industry Case Studies
Figure 9. Biotechnology Case Studies
Figure 10. Medical Care Case Studies
Figure 11. Education and Research Case Studies
Figure 12. Other Case Studies
Figure 13. Cancer Monoclonal Antibody Partnering Terms and Agreements Report Years Considered
Figure 14. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 15. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Region: 2022 VS 2029
Figure 17. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Players in 2022
Figure 18. Global Top Cancer Monoclonal Antibody Partnering Terms and Agreements Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in 2022
Figure 20. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Country (2018-2029)
Figure 22. United States Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Canada Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Country (2018-2029)
Figure 26. Germany Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. France Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. U.K. Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Italy Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Russia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Nordic Countries Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Region (2018-2029)
Figure 34. China Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Japan Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. South Korea Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Southeast Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. India Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Australia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Country (2018-2029)
Figure 42. Mexico Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Brazil Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Country (2018-2029)
Figure 46. Turkey Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Saudi Arabia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. 3SBio Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
Figure 49. 4D Pharma Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
Figure 50. Abbvie Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
Figure 51. Abzena Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
Figure 52. Adaptive Biotechnologies Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
Figure 53. Aeglea BioTherapeutics Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
Figure 54. Agenus Bio Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
Figure 55. Ascension Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
Figure 56. Ascentage Pharma Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
Figure 57. Aslan Pharma Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
Figure 58. Telix Pharmaceuticals Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
Figure 59. Basilea Pharmaceutica Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
Figure 60. Bavarian Nordic Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
Figure 61. Baxalta Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
Figure 62. Bayer Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
Figure 63. Cantargia Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
Figure 64. Apollomics Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
Figure 65. Chiome Bioscience Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
Figure 66. Clovis Oncology Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2018-2023)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed

REPORT PURCHASE OPTIONS

USD Single User Price
USD Multi User Price
USD Enterprise Price

---- OR ----

Frequently Asked Questions ?

  • Upto 24 hrs - Working days
  • Upto 48 hrs max - Weekends and public holidays
  • Single User License
    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License
    A license granted to multiple users.

  • Site License
    A license granted to a single business site/establishment.

  • Corporate License, Global License
    A license granted to all employees within organisation access to the product.
  • Online Payments with PayPal and CCavenue
  • Wire Transfer/Bank Transfer
  • Email
  • Hard Copy

Our Key Features

  • Data Accuracy and Reliability
  • Data Security
  • Customized Research
  • Trustworthy
  • Competitive Offerings
check discount